iShares Neuroscience and Healthcare ETF Rating $20.47 +0.47 (+2.35%) As of 04/17/2025 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsBuy This Stock iShares Neuroscience and Healthcare ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.IBRN Aggregate RatingModerate Buy 2.81Holdings in IBRN have an aggregate rating of Moderate Buy based on 389 analyst ratings issued in the past year covering 40 companies (81.0% of the portfolio).IBRN Aggregate Price Target$20.47High Prediction$20.47Average Prediction$20.47Low Prediction$20.47Holdings in IBRN have an aggregate price target of $20.47 and a range of $20.47 to $20.47 covering 40 companies (81.0% of the portfolio).IBRN Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy24 Buy rating(s)Moderate Buy12 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by iShares Neuroscience and Healthcare ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 40 IBRN Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.42%CPRXCatalyst Pharmaceuticals$22.52+1.5%4.6051 of 5 stars3.13$32.29 43.4%8Positive NewsGap Down4.83%ARGXargenx$596.20+1.5%3.2733 of 5 stars2.91$699.28 17.3%23Analyst Forecast4.58%SUPNSupernus Pharmaceuticals$30.76+0.2%2.9353 of 5 stars2.33$36.00 17.0%3Analyst UpgradeNews Coverage4.52%ALKSAlkermes$27.05-0.5%4.6435 of 5 stars2.67$38.50 42.3%12Short Interest ↓Analyst Revision4.52%ACADACADIA Pharmaceuticals$14.73+1.1%4.0239 of 5 stars2.50$23.93 62.5%16Analyst RevisionPositive NewsGap Down4.37%NBIXNeurocrine Biosciences$101.38+1.3%4.8264 of 5 stars2.91$161.86 59.7%23Analyst UpgradeAnalyst Revision4.24%PTCTPTC Therapeutics$47.39+2.1%3.8618 of 5 stars2.53$63.77 34.6%15Upcoming EarningsShort Interest ↑News Coverage4.21%BIIBBiogen$118.61+2.9%4.6773 of 5 stars2.42$213.15 79.7%31Upcoming EarningsAnalyst ForecastAnalyst Revision4.16%XENEXenon Pharmaceuticals$35.14+4.0%2.7469 of 5 stars3.00$56.78 61.6%10Analyst DowngradeOptions VolumeAnalyst RevisionNews Coverage3.86%SRRKScholar Rock$30.71+3.2%3.8936 of 5 stars3.00$42.67 39.0%6News CoveragePositive News3.64%DNLIDenali Therapeutics$12.74+1.5%4.0931 of 5 stars3.00$37.57 194.9%173.40%IARTIntegra LifeSciences$15.83+0.5%4.2466 of 5 stars1.89$22.71 43.5%9Short Interest ↓3.21%BHVNBiohaven$20.41+9.2%3.6485 of 5 stars3.07$62.77 207.6%15Analyst Revision2.73%SRPTSarepta Therapeutics$53.79-0.3%4.673 of 5 stars2.83$161.83 200.8%24Gap Down2.03%EWTXEdgewise Therapeutics$13.41+2.9%2.2834 of 5 stars2.75$40.38 201.2%8Gap Up1.82%DYNDyne Therapeutics$8.17+4.3%3.519 of 5 stars3.07$47.46 480.9%151.78%AXGNAxoGen$15.57-0.1%2.9593 of 5 stars3.00$22.60 45.2%5Short Interest ↑News CoveragePositive News1.77%AVXLAnavex Life Sciences$8.95+1.2%3.4403 of 5 stars3.33$44.00 391.6%31.60%PRAXPraxis Precision Medicines$33.79+13.3%2.9909 of 5 stars2.78$123.33 265.0%9Positive News1.57%AVDLAvadel Pharmaceuticals$8.03-1.5%2.4931 of 5 stars3.00$19.88 147.5%8Analyst RevisionNews Coverage1.21%PRTAProthena$9.20-0.6%3.1549 of 5 stars2.75$55.00 497.8%8News Coverage0.98%CBLLCeriBell$14.85+2.5%N/A3.00$32.50 118.9%7High Trading Volume0.97%ZVRAZevra Therapeutics$7.15+1.4%2.6533 of 5 stars3.11$22.29 211.7%9News CoverageGap Down0.95%CAPRCapricor Therapeutics$11.25+16.7%1.9612 of 5 stars3.00$34.50 206.7%6Options VolumeNews CoverageGap Up0.83%DNTHDianthus Therapeutics$19.50+2.7%2.0918 of 5 stars3.22$54.33 178.6%9News CoverageGap Down0.74%RGNXREGENXBIO$5.94-3.6%4.6802 of 5 stars2.83$31.63 432.4%6Analyst ForecastAnalyst RevisionNews CoveragePositive News0.73%NPCENeuroPace$10.79+3.5%3.0305 of 5 stars2.80$15.20 40.9%5Short Interest ↑Gap Down0.69%CLPTClearPoint Neuro$12.24+6.3%2.1162 of 5 stars3.00$25.00 104.2%3News CoverageGap Up0.59%VNDAVanda Pharmaceuticals$4.33-0.9%4.1647 of 5 stars3.00$16.50 281.1%2News Coverage0.59%DRUGBright Minds Biosciences$33.11+3.4%3.0098 of 5 stars3.20$84.33 154.7%5News CoverageGap Up0.58%AMLXAmylyx Pharmaceuticals$3.98+4.2%3.1056 of 5 stars2.86$8.00 101.0%7Analyst Revision0.51%TSHATaysha Gene Therapies$1.24+5.1%3.0072 of 5 stars3.00$6.63 434.3%80.49%SLDBSolid Biosciences$2.55+1.2%3.4465 of 5 stars3.33$15.67 514.4%12Positive News0.46%TRDAEntrada Therapeutics$8.13+3.4%2.9754 of 5 stars3.25$25.67 215.7%4Positive News0.46%ABEOAbeona Therapeutics$4.84-0.2%4.1945 of 5 stars3.00$17.50 261.6%4Positive News0.43%ANNXAnnexon$1.46+2.1%2.6352 of 5 stars3.00$18.67 1,178.5%4Short Interest ↓News CoveragePositive News0.42%RAPPRapport Therapeutics$10.15+4.0%1.6599 of 5 stars3.00$32.67 221.8%4Short Interest ↑0.40%NGNENeurogene$11.49+6.7%2.1281 of 5 stars3.13$47.20 310.8%80.37%VYGRVoyager Therapeutics$3.16+1.0%4.4569 of 5 stars3.11$13.97 342.0%9Analyst Revision0.33%FULCFulcrum Therapeutics$3.29+7.5%2.2458 of 5 stars2.11$8.63 162.2%9Short Interest ↓News CoveragePositive News This page (NYSEARCA:IBRN) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Neuroscience and Healthcare ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Neuroscience and Healthcare ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
